PAHC vs. EXEL

Last updated Apr 1, 2026

Compare and contrast key facts about Phibro Animal Health Corporation (PAHC) and Exelixis, Inc. (EXEL).

Performance

PAHC vs. EXEL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Phibro Animal Health Corporation (PAHC) and Exelixis, Inc. (EXEL). The values are adjusted to include any dividend payments, if applicable.

PAHC vs. EXEL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
PAHC Phibro Animal Health Corporation	48.39%	80.76%	86.30%	-10.42%	-32.33%	7.28%	-20.09%	-21.31%	-3.00%	15.75%
EXEL Exelixis, Inc.	-2.14%	31.62%	38.81%	49.56%	-12.25%	-8.92%	13.90%	-10.42%	-35.30%	103.89%

Fundamentals

Market Cap PAHC : $2.27B EXEL : $12.09B
EPS PAHC : $2.25 EXEL : $2.76
PE Ratio PAHC : 24.53 EXEL : 15.52
PEG Ratio PAHC : 0.06 EXEL : 0.27
PS Ratio PAHC : 1.54 EXEL : 5.24
PB Ratio PAHC : 6.82 EXEL : 5.59
Total Revenue (TTM) PAHC : $1.46B EXEL : $2.32B
Gross Profit (TTM) PAHC : $467.02M EXEL : $2.24B
EBITDA (TTM) PAHC : $209.00M EXEL : $934.65M

Returns By Period

In the year-to-date period, PAHC achieves a 48.39% return, which is significantly higher than EXEL's -2.14% return. Over the past 10 years, PAHC has underperformed EXEL with an annualized return of 9.53%, while EXEL has yielded a comparatively higher 26.62% annualized return.

PAHC

• 1D: 3.67%
• 1M: 1.55%
• YTD: 48.39%
• 6M: 37.39%
• 1Y: 162.39%
• 3Y*: 57.25%
• 5Y*: 20.22%
• 10Y*: 9.53%

EXEL

• 1D: 2.24%
• 1M: -2.66%
• YTD: -2.14%
• 6M: 3.85%
• 1Y: 16.17%
• 3Y*: 30.25%
• 5Y*: 13.15%
• 10Y*: 26.62%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

PAHC vs. EXEL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PAHC

PAHC Risk / Return Rank: 96
PAHC Sharpe Ratio Rank: 97
PAHC Sortino Ratio Rank: 97
PAHC Omega Ratio Rank: 94
PAHC Calmar Ratio Rank: 96
PAHC Martin Ratio Rank: 96

EXEL

EXEL Risk / Return Rank: 56
EXEL Sharpe Ratio Rank: 56
EXEL Sortino Ratio Rank: 52
EXEL Omega Ratio Rank: 54
EXEL Calmar Ratio Rank: 58
EXEL Martin Ratio Rank: 58

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PAHC vs. EXEL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Phibro Animal Health Corporation (PAHC) and Exelixis, Inc. (EXEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PAHC	EXEL	Difference
Sharpe ratio Return per unit of total volatility	3.09	0.37	+2.72
Sortino ratio Return per unit of downside risk	3.96	0.83	+3.12
Omega ratio Gain probability vs. loss probability	1.48	1.12	+0.36
Calmar ratio Return relative to maximum drawdown	6.51	0.67	+5.84
Martin ratio Return relative to average drawdown	17.67	1.55	+16.11
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PAHC vs. EXEL - Sharpe Ratio Comparison

The current PAHC Sharpe Ratio is 3.09, which is higher than the EXEL Sharpe Ratio of 0.37. The chart below compares the historical Sharpe Ratios of PAHC and EXEL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	PAHC	EXEL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.09	0.37	+2.72
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.45	0.36	+0.09
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.22	0.60	-0.38
Sharpe Ratio (All Time) Calculated using the full available price history	0.29	0.07	+0.23

Correlation

The correlation between PAHC and EXEL is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

PAHC vs. EXEL - Dividend Comparison

PAHC's dividend yield for the trailing twelve months is around 0.87%, while EXEL has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
PAHC Phibro Animal Health Corporation	0.87%	1.28%	2.29%	4.15%	3.58%	2.35%	2.47%	1.93%	1.31%	1.19%	1.37%	1.33%
EXEL Exelixis, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

PAHC vs. EXEL - Drawdown Comparison

The maximum PAHC drawdown since its inception was -79.62%, smaller than the maximum EXEL drawdown of -97.38%. Use the drawdown chart below to compare losses from any high point for PAHC and EXEL.

Drawdown Indicators

	PAHC	EXEL	Difference
Max Drawdown Largest peak-to-trough decline	-79.62%	-97.38%	+17.76%
Max Drawdown (1Y) Largest decline over 1 year	-24.76%	-25.34%	+0.58%
Max Drawdown (5Y) Largest decline over 5 years	-65.71%	-41.47%	-24.24%
Max Drawdown (10Y) Largest decline over 10 years	-79.62%	-57.20%	-22.42%
Current Drawdown Current decline from peak	-2.98%	-12.91%	+9.93%
Average Drawdown Average peak-to-trough decline	-39.25%	-71.55%	+32.30%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.12%	10.85%	-1.73%

Volatility

PAHC vs. EXEL - Volatility Comparison

Phibro Animal Health Corporation (PAHC) has a higher volatility of 13.78% compared to Exelixis, Inc. (EXEL) at 6.86%. This indicates that PAHC's price experiences larger fluctuations and is considered to be riskier than EXEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PAHC	EXEL	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.78%	6.86%	+6.92%
Volatility (6M) Calculated over the trailing 6-month period	34.47%	26.58%	+7.89%
Volatility (1Y) Calculated over the trailing 1-year period	52.95%	43.76%	+9.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	44.85%	36.84%	+8.01%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	43.68%	44.88%	-1.20%

Financials

PAHC vs. EXEL - Profitability Comparison

The chart below illustrates the profitability comparison between Phibro Animal Health Corporation and Exelixis, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

PAHC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Phibro Animal Health Corporation reported a gross profit of 132.66M and revenue of 373.91M. Therefore, the gross margin over that period was 35.5%.

EXEL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported a gross profit of 572.18M and revenue of 598.66M. Therefore, the gross margin over that period was 95.6%.

PAHC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Phibro Animal Health Corporation reported an operating income of 50.33M and revenue of 373.91M, resulting in an operating margin of 13.5%.

EXEL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported an operating income of 235.22M and revenue of 598.66M, resulting in an operating margin of 39.3%.

PAHC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Phibro Animal Health Corporation reported a net income of 27.46M and revenue of 373.91M, resulting in a net margin of 7.3%.

EXEL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported a net income of 244.53M and revenue of 598.66M, resulting in a net margin of 40.9%.